Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Benzimidazoles
Female
fms-Like Tyrosine Kinase 3
Genes, ras
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Mitogen-Activated Protein Kinase Kinases
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-kit
Treatment Outcome

authors with profiles

Christopher Winslow
Walter M. Stadler
Olatoyosi Odenike
Theodore Karrison
Wendy Stock
Loren Joseph
Richard A. Larson